Combination of intrahepatic TARE and extrahepatic TACE to treat HCC patients with extrahepatic artery supply: A case series.

Extrahepatic artery HCC TACE TARE

Journal

Research in diagnostic and interventional imaging
ISSN: 2772-6525
Titre abrégé: Res Diagn Interv Imaging
Pays: France
ID NLM: 9918574385706676

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 19 10 2023
accepted: 24 02 2024
medline: 30 7 2024
pubmed: 30 7 2024
entrez: 30 7 2024
Statut: epublish

Résumé

The aim of this study was to report the safety and tumor response rate of combined transarterial radioembolization (TARE) through the intrahepatic arteries and transarterial chemoembolization (TACE) through the extrahepatic feeding arteries (EHFA) in patients with hepatocellular carcinoma (HCC). Patients with HCC, who had both intrahepatic and extrahepatic arterial supply visible on preinterventional multiphase CT and were treated between 2016 and 2021 with a combination of TACE and TARE on the same nodule, were retrospectively included. Epidemiological, clinical, biological, and radiological characteristics were recorded. Safety and tumor response were assessed at 6 months. Nine patients (8 men, median age 62 years [IQR: 54-72 years]) were included. Seven patients had previous treatments on the target nodule (TARE: 5; TACE: 2). The median longest axis (LA) of the lesion was 70 mm (IQR: 60-79 mm). Three patients had portal vein invasion (VP3). The EHFA originated from the right diaphragmatic artery ( The combination of TARE and extrahepatic TACE for HCC with both intrahepatic and extrahepatic arterial supplies seems feasible and safe. Further studies are needed to validate the effectiveness of these preliminary results.

Identifiants

pubmed: 39076578
doi: 10.1016/j.redii.2024.100042
pii: S2772-6525(24)00003-6
pmc: PMC11265365
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100042

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

Authors declare that they do not have any conflict of interest.

Auteurs

Lorenzo Carlo Pescatori (LC)

Department of Interventional Radiology, hôpital Avicenne (AP-HP), Bobigny, France.

Athena Galletto Pregliasco (A)

Department of Radiology, hôpital Henri-Mondor (AP-HP), Créteil, France.

Haytham Derbel (H)

Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.
Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.

Laetitia Saccenti (L)

Department of Radiology, hôpital Henri-Mondor (AP-HP), Créteil, France.
Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.

Mario Ghosn (M)

Department of Radiology, hôpital Henri-Mondor (AP-HP), Créteil, France.

Maxime Blain (M)

Department of Radiology, hôpital Henri-Mondor (AP-HP), Créteil, France.

Julia Chalayea (J)

Department of Nuclear Medicine, hôpital Henri-Mondor (AP-HP), Créteil, France.

Alain Luciani (A)

Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.
Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.

Sebastien Mulé (S)

Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.
Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.

Giuliana Amaddeo (G)

Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.
Department of Hepatology, hôpital Henri-Mondor (AP-HP), Créteil, France.

Hicham Kobeiter (H)

Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.
Inserm IMRB U955, équipe 8, université Paris-Est Créteil, Créteil, France.

Vania Tacher (V)

Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.
Inserm IMRB U955, équipe 18, université Paris-Est Créteil, Créteil, France.

Classifications MeSH